FDA’s Pediatric Data-Extrapolation Policies Questioned At Asthma Panel
Should using adult data to label a product for kids be ‘a judgment call?’ Advisory committee asks whether FDA needs more explicit criteria during review of GSK’s Breo Ellipta.
You may also be interested in...
Mepolizumab seems headed for approval in severe asthma – but only in adults; adolescent data in pivotal studies were promising, but too limited.
With a high regulatory bar for safety and efficacy for new asthma drugs and a skeptical payer base, the significance of and effect on eosinophil counts will be a crucial consideration for the severe asthma candidate.
FDA approves GlaxoSmithKline’s LABA/inhaled corticosteroid combo for asthma in adults but says more data needed in adolescents. GSK plans to throw additional promotional support behind the existing pediatric asthma claim for Advair, which is expected to face generic competition in the coming years.